5 unchanged sentences
Method of Filing
−Removed: Employment Agreement, effective May 18, 2022, by and between the Company and Raven Jaeger, M.S.
−Removed: Incorporated by reference to Exhibit 10.1 to the Company's Current Report on Form 8-K filed June 28, 2022
Certification of Chief Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 and SEC Rule 13a-14(a)
8 unchanged sentences
Furnished herewith
−Removed: The following materials from Diffusion’s quarterly report on Form 10-Q for the quarter ended June 30, 2022 formatted in inline XBRL (Extensible Business Reporting Language):
+Added: The following materials from Diffusion’s quarterly report on Form 10-Q for the quarter ended September 30, 2022 formatted in Inline XBRL (Extensible Business Reporting Language):
(i) the Unaudited Consolidated Balance Sheets, (ii) the Unaudited Consolidated Statements of Operations, (iii) the Unaudited Consolidated Statement of Changes in Stockholders’ Equity (Deficit), (iv) the Unaudited Consolidated Statements of Cash Flows, and (v) Notes to Unaudited Consolidated Financial Statements
2 unchanged sentences
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
−Removed: August 11, 2022
+Added: November 14, 2022
DIFFUSION PHARMACEUTICALS INC.
/s/ Robert J.
−Removed: President and Chief Executive Officer
+Added: President and Chief Executive
(Principal Executive Officer)
2 unchanged sentences
Chief Financial Officer
−Removed: (Principal Financial Officer and Principal Accounting Officer)
+Added: (Principal Financial Officer
+Added: and Principal Accounting
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.